Highlights do ESMO BREAST 2022

Dra. Angélica Nogueira, Oncologista Clínica, professora da Universidade Federal de Minas Gerais (UFMG) e presidente do Grupo Brasileiro de Tumores Ginecológicos, comenta sobre os principais trabalhos que foram apresentados no Congresso ESMO Breast Cancer de 2022  

São abordados trabalhos para doença avançada, doença inicial além de trabalhos que propõem atualizações e inclusão de novos biomarcadores.  

No vídeo, Dra. Angélica faz uma análise completa dos resultados de oito estudos, além de destacar as implicações práticas dos achados. Assista o vídeo e confira o conteúdo completo! 

Referências: 

1. Bartsch, R., et al. “165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial.” Annals of Oncology 33 (2022): S198. 
2. Neven, P., et al. “LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB)+ fulvestrant (FUL).” Annals of Oncology 33 (2022): S194. 
3. Tutt, A., et al. “161O VIOLETTE: Randomised phase II study of olaparib (ola)+ ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC).” Annals of Oncology 33 (2022): S194-S195. 
4. Prat, A., et al. “LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial.” Annals of Oncology 33 (2022): S164. 
5. Jerusalem, G., et al. “92MO Neoadjuvant nivolumab (NIVO)+ palbociclib (PALBO)+ anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8.” Annals of Oncology 33 (2022): S165-S166. 
6. Toi, M., et al. “59MO Adjuvant abemaciclib combined with endocrine therapy (ET): Efficacy results in monarchE cohort 1.” Annals of Oncology 33 (2022): S149. 
7. Mosele, M. F., et al. “LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial.” Annals of Oncology 33 (2022): S123. 
8. Tarantino, P., et al. “1MO Prognostic and biologic significance of HER2-low expression in early breast cancer.” Annals of Oncology 33 (2022): S124.